Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
about
AbaloparatideIdentification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meetingRecent advances in the management of osteoporosisProfile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation.Osteoporosis Therapy: Bone Modeling during Growth and Aging.Parathyroid Hormone-Related Protein, Its Regulation of Cartilage and Bone Development, and Role in Treating Bone Diseases.Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.Abaloparatide: First Global Approval.Osteoporosis treatment: recent developments and ongoing challenges.The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.High dose teriparatide (rPTH1-34) therapy increases callus volume and enhances radiographic healing at 8-weeks in a massive canine femoral allograft model.Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.Emerging anabolic agents in the treatment of osteoporosis.Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.Anabolic agents: what is beyond osteoporosis?Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis TherapyParathyroid Hormone Signaling in OsteocytesTreatment of Osteoporosis: Unmet Needs and Emerging SolutionsRethinking Bone Disease in Kidney Disease
P2860
Q28073605-35E816F5-5098-4589-BF36-BEB3BDFEFB92Q30234621-C71670AB-DC52-47D5-BC7C-65FA3E444B94Q33672136-4F66F5DD-DC47-4BBE-9B7E-6DF1FDDCB26FQ33860563-88BA2CC0-D1D3-45A4-A497-D788942E7D5FQ37580945-AA50C052-8097-469F-8C1A-A1C2B21A02DCQ37689421-4E8380B0-A0D0-474A-805D-1A2B8F2E921FQ38824663-ECA09034-FD82-4312-A878-3F752471885BQ39183207-6BBDE22D-DD86-40CB-B281-1AAF06EAC64DQ39283452-7DB977AF-34EC-43D3-87D8-8CA19FAA5FC5Q39380393-5178F82C-027C-4D57-80E7-BECC9EA21A2DQ39423904-64E5BF33-5777-4EF1-9643-6CA9B5DCDD3CQ40214077-5D985F12-CFFD-4637-BE5B-F34182CF38DCQ40588003-934DEEA9-AF33-488B-BB9F-67A080C844C9Q42014841-782EA48F-8E97-44C8-AF04-7F26044E6D64Q42650829-FBF13334-A8C1-4393-847B-BC898C41C169Q47309439-B068A99E-6A25-4334-AF3E-66260C79B331Q47321862-AC3CFDE7-ED53-4D32-ABA1-54E9AAC3F54DQ47416630-92D5FB84-87E6-473B-9CD3-C22FC935C20CQ47428797-65C4AE9F-9BF9-406A-9EFB-1B53B5B2FD70Q48012226-E68A1428-1B2A-496C-9A21-B4B5CD7B8F2DQ48160184-9B51CA46-5BCE-468C-9EF5-0509B6DA8D1BQ49038526-6C84DD94-BA72-4CCB-A2B5-B9CF4F043A89Q49505161-ED3FB0F7-0875-4EDC-8E24-40B64B7AB0C3Q49925714-B7BE4F68-59DE-49E0-80E0-E9B9C2B6993FQ50094533-4606C376-A886-49B1-86EF-AC172AB26CFCQ52600423-0C035489-4D80-4177-8E3D-BF627AB35683Q57147876-D0220458-0C9B-46DC-8A5C-40D460B8B67DQ57151535-9F2582A3-9873-4F22-B37D-034A564B6D10Q58780149-B2161C4B-E0A6-4CF4-A3B3-3461BEFF4273Q59126536-B468B9FF-BC53-4FD2-AA05-4EB616931033
P2860
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@ast
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@en
type
label
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@ast
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@en
prefLabel
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@ast
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@en
P2093
P2860
P356
P1433
P1476
Binding Selectivity of Abalopa ...... fects on Downstream Signaling.
@en
P2093
Braden A Corbin
Gary Hattersley
Hila Bahar
Thomas Dean
Thomas J Gardella
P2860
P304
P356
10.1210/EN.2015-1726
P407
P577
2015-11-12T00:00:00Z